GeneBioTech

At a glance

GeneBioTech filed 26 disclosures in the last 12 months, including 9 5% holder. The most recent key filing was on Oct 27: A major holder's stake rose from 0.00% to 5.01%.

Revenue for 2025 was ₩90.8B, up 9.4% on 2024. Operating margin was 4.3% against 4.6% a year earlier. Debt was 38% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩44.5B and operating profit of ₩2.3B.

The 2025 annual report lists 45 employees with an average tenure of 7 years and average pay of ₩44.8M. Its 5 directors and auditors were paid ₩54.5M each on average. It paid ₩50 per common share in cash dividends. 이찬호 and related parties held 28.64% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 5.01% on Oct 27.

From the 2025 annual report

Staff: 45 (34 men, 11 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩2B. Directors and auditors: 5, paid ₩272.3M in total.

Dividends (common shares)

Largest shareholder

이찬호 holds 28.09%; with 2 related parties the group holds 28.64% of common shares at year end.

Auditor: 인덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports